Aligos Therapeutics has licensed Greater China rights to its oral HBV capsid assembly modulator, pevifoscorvir sodium (ALG-000184), to Xiamen Amoytop Biotech for $25 million upfront, up to $420 million in milestones, and tiered high single-digit royalties. The deal covers mainland China, Taiwan, Hong Kong, and Macau, while Aligos retains rights elsewhere and the ability to run clinical trials in the region. The transaction, subject to Amoytop shareholder approval, bolsters Aligos’s cash runway into the fourth quarter of 2026 and positions pevifoscorvir within Amoytop’s established HBV franchise.
The move is a pragmatic bet on the combination-therapy thesis in chronic HBV and a capital-efficient way to pressure-test a potentially class-defining asset in the world’s largest HBV market. Rather than push into China alone, Aligos is tapping a local commercial engine already selling pegylated interferon and co-developing an antisense oligonucleotide, creating an integrated pathway to test dual and triple regimens under one roof. For a small-cap biotech navigating a tight funding environment, swapping regional rights for non-dilutive cash while preserving global optionality reflects disciplined portfolio strategy.
This matters now because HBV remains a stubborn outlier in viral therapeutics, with more than 90 million people affected in Greater China and standard-of-care nucleos(t)ide analogs delivering lifelong suppression but little functional cure. A potent oral CAM-E that reduces viral replication, limits integration, and chips away at cccDNA could redefine chronic suppression benchmarks and serve as a backbone for curative combinations. For patients and hepatologists, the promise is shorter, more potent regimens with deeper antigen declines; for payers, the bar is evidence that premium combinations deliver durable outcomes that justify costs beyond ubiquitous generics like TDF and entecavir. The NMPA’s recognition of a chronic suppression regulatory pathway gives Amoytop a nearer-term approval vector, but real-world evidence on HBsAg loss, HBcrAg reductions, and relapse durability will be pivotal for NRDL negotiations and provincial tenders.
For competitors, the deal underscores a consolidating HBV playbook: pair direct-acting antivirals such as CAMs with gene-silencing or immune-modulating agents, and anchor on biomarker-driven endpoints that translate into durable clinical benefit. It also reinforces a broader industry pattern in 2025–2026: Western biotechs monetizing regional rights to extend runway while Chinese biopharmas assemble specialty portfolios in categories with entrenched clinical infrastructure. The partnership could accelerate development timelines, as Aligos can include high-prevalence Chinese cohorts in global studies while Amoytop mobilizes hepatology field forces and trial networks to execute combination designs that might be operationally harder for a foreign sponsor.
Commercially, success will hinge on whether pevifoscorvir can show clear superiority versus NA backbones in Phase 2 b-SUPREME, which is running against tenofovir with an interim analysis expected in the second half of 2026 and topline data in 2027. If biomarker separation and safety hold, Amoytop can craft a stepwise launch: first securing a chronic suppression label, then layering interferon or ASO combinations to chase deeper responses, using outcome-based contracts or staged NRDL submissions to manage budget impact. Brand teams should plan for center-of-excellence activation, diagnostic readiness for antigen and HBcrAg monitoring, and patient management protocols to manage intensified, time-limited therapy.
The strategic question now is whether pevifoscorvir becomes the preferred oral backbone for next-wave HBV combinations. If interim data deliver meaningful HBsAg and cccDNA signals, expect renewed partnering outside China and heightened competitive pressure on other CAMs and oligo programs; if not, the market may consolidate around fewer, stronger backbones. The next inflection is clear: can this China-first combination platform generate the real-world and controlled-trial evidence needed to reset HBV treatment goals from chronic maintenance to time-bound, durable suppression?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
